Your Competitor Isn't Another Startup. It's "Wait for Epic."

Key Takeaways

• 71% of surveyed health system executives prioritize implementing Epic modules whenever possible, and 0% prefer external vendors by default — which means the alternative to your product is usually a roadmap, not a rival logo. — Redesign Health, "The Epic Effect" (112 executives at Epic-based health systems)
• 91% have complete or significant confidence that Epic will deliver AI matching best-in-class external vendors, and 80% expect Epic to become an even greater priority over the next three to five years — the default is not passive, it is actively trusted. — Redesign Health, "The Epic Effect"
• 78% require external startups to demonstrate higher ROI than Epic solutions, and 49% require a "significantly higher" return — the ROI bar for a non-Epic purchase is structurally raised before your first call. — HIT Consultant reporting on The Epic Effect
• The default softens the moment the wait is priced: offered 18 months for an EHR-native feature versus a three-month third-party deployment with guaranteed ROI, only 22% of senior health system IT leaders would wait — down from 52% a year earlier. — Qventus survey of 60+ CIOs, chief AI officers and CMIOs, via Fierce Healthcare
• 92% of surveyed health systems run pre-deployment testing on AI, while just 4% describe their AI strategy as advanced — buyers are testing you against a standard they are still building, so evidence beats persuasion. — Center for Connected Medicine at UPMC with KLAS Research (27 health systems), via HIT Consultant

Open almost any Series A–C health-tech deck and you will find a competitive matrix. Three or four rival logos, a row of checkmarks, a green column on the left. It is a careful slide, and it is answering a question the buyer is not asking.

The health system evaluating you is not choosing between you and the other names on that grid. It is choosing between you and something it already paid for, from a vendor it already trusts, running inside a system it already operates. That option has no sales cycle, no new security review, and no integration risk. It has a delivery date.

Your competitor is a date. And the only argument that beats a date is the honest cost of waiting for it — an argument most health-tech marketing never makes, because making it requires quantifying the buyer's downside instead of describing your upside.

The Competitor You Left Off the Slide

The numbers on the default are blunt. In Redesign Health's "The Epic Effect" survey of 112 senior executives at Epic-based health systems — CEOs, CIOs, CMIOs and VPs, fielded October 2025 through March 2026 — 71% said their organization prioritizes implementing Epic modules whenever possible. Zero percent said they prefer to bring in external vendors first.

Not a small number. Zero. There is no meaningful population of health systems in that sample walking into an AI evaluation predisposed toward the outside option.

What makes the default durable is not inertia. It is confidence. Ninety-one percent of those executives reported complete or significant confidence that Epic will deliver AI solutions matching best-in-class external vendors, and 80% expect Epic to become an even greater priority over the next three to five years. The buyer is not settling for the default. They believe in it.

Two caveats worth holding onto, because they shape how you use this. The survey covers Epic-based systems and skews toward community systems; it does not describe how Oracle Health, MEDITECH or Athena environments buy. And none of this is a knock on Epic. A platform that consolidates trust, budget and integration surface is doing exactly what a good platform does. The problem is not vendor conduct. It is that most health-tech positioning is built as though that platform were not in the room.

What "Epic-First" Actually Costs You at the Deal Level

The tax is measurable, and it shows up in two places.

The first is the return threshold. According to HIT Consultant's reporting on the study, 78% of executives require external startups to demonstrate a higher ROI than Epic solutions — 49% require a "significantly higher" return. Parity does not win. A product that performs as well as the native module, at the same price, loses on switching cost alone.

The second is budget surface. Redesign Health's survey found roughly 61% of clinical and administrative IS budget allocated to Epic, leaving about 39% for everyone else. Every external vendor in every category competes inside that minority share.

Put those together and the picture stops being about competitive differentiation. You are not fighting for the biggest slice of a category budget. You are fighting for a slice of the leftover, against a higher bar, on a shorter clock. That is a pricing and proof problem long before it is a features problem — and it is decided in the research phase, months before a rep is on the call.

This is why "we're 3x faster than Vendor X" lands flat in a health system evaluation. The comparison is real and the buyer does not care, because Vendor X is not the alternative they are weighing.

The Crack in the Door

Here is the tension the data actually describes, and it is not a contradiction: the same executives who run an Epic-first posture are open to buying from companies with almost no track record. Sixty-four percent of that sample rated themselves likely or very likely to purchase from a net-new startup — defined in the survey as one with three or fewer live customers. Only 6% expect to shift toward external best-in-breed solutions overall.

Read those together and the shape is clear. The default is strong, it is getting stronger, and it is still displaceable in specific situations. "Epic-first" is not "Epic-only."

The willingness to wait is also collapsing, and faster than most positioning has caught up with. In a Qventus survey of more than 60 senior health system IT leaders — CIOs, chief AI officers and CMIOs at medium and large systems — respondents were asked whether they would wait 18 months for an AI feature from their EHR or deploy a third-party solution in three months with guaranteed ROI. Only 22% would wait, down from 52% the year before. Separately, 74% named EHR vendor reliance as an obstacle to executing their AI strategy.

That is the whole opening. The default holds right up until someone puts a number on the delay.

Six things move a health system off its EHR default:

1. A gap the platform is not positioned to close. Executives in the Epic Effect named clinician-facing AI (48%), imaging diagnostics (44%) and patient engagement (40%) as the domains where startups can still compete.
2. A priced wait. Not "we're available now" — 18 months of a specific, quantified operational cost versus three months to deployment.
3. An ROI case built to clear a raised bar. If 78% require more than parity, your business case has to open above parity rather than argue its way there.
4. Integration that runs through the existing workflow, not around it. The switching cost is the objection. Anything that reduces it is the answer.
5. Evidence a validation committee can actually test. Not testimonials. Something their team can run.
6. A contract short enough to let them exit. Short terms lower the stakes of choosing you, and health systems are already writing them.

Notice that only one of those six is about your product. The rest are marketing and positioning decisions, and every one of them gets made — or missed — before sales gets involved.

Marketing That Survives Validation

Your content is not being read anymore. It is being tested.

The Center for Connected Medicine at UPMC and KLAS Research surveyed C-suite, clinical informatics and IT executives across 27 health systems and found that 92% conduct pre-deployment testing of AI and 93% have already deployed third-party AI. Yet only 4% describe their AI strategy as advanced, while 63% call theirs developing or ad hoc. Fewer than half — 44% — have a dedicated data platform or sandbox to validate accuracy, safety and drift.

That combination is the operative fact for anyone building a health-tech funnel. Your buyer will test you rigorously, against criteria they have not finished writing. They are assembling the evaluation standard while running the evaluation.

Which means the highest-value asset you can publish is not a persuasive one. It is a usable one: the evaluation criteria, the validation protocol, the integration requirements, the failure modes. Give a committee that is inventing its own rubric a credible rubric, and you have influenced the standard you will be judged against. That is a content strategy decision, not a sales-enablement afterthought.

Track record matters too, and it cuts both ways. In PHTI's 2025 State of Digital Health Purchasing survey — 309 decision-makers across U.S. health plans, employers and health systems, fielded in August 2025 — health plans and health systems focus on vendors' track records, while employers prioritize cost. And 73% of contracts run two years or less, with more than half of organizations reviewing their digital health offerings annually. A short contract is your way in and your clock. You will be asked to prove value inside a window that starts the day you sign.

There is a funding reason this is getting harder, not easier. Rock Health's H1 2026 market overview reports that U.S. digital health startups raised $7.4B across 244 deals, with 20 megadeals across 19 companies taking 45% of all capital — up from 42% in 2025 and 22% in 2024. Just over 8% of deals absorbed nearly half the money. Capital is concentrating, which means most companies will make this argument without a megaround behind them. Evidence has to do the work that spend used to.

The Cost-of-Delay Page Every Health-Tech Site Is Missing

Almost no health-tech site has one, and it is the single asset best matched to how these decisions actually get made.

It is not a comparison page against a rival vendor, and it is not an Epic takedown. It is a page that answers one question honestly: what does a health system spend, forgo or absorb in the months between now and the native feature arriving? Built well, it contains:

• The delay window, stated plainly. Whatever your category's realistic wait looks like, sourced and dated, not implied.
• A cost model the buyer can run with their own inputs. Their volumes, their staffing, their margins. Not your averages.
• The integration answer up front. Where you sit relative to the platform, and what the migration path looks like if the native module ships later.
• The validation package. What their team can test, in what environment, over what period.
• The exit terms. Contract length, offboarding, data portability.

Sign it with a clinical and a financial name, not a marketing byline — the committee reading it includes both. Put it in the research phase, indexed and ungated, where a CMIO finds it at 11 p.m. three months before anyone contacts you. Gating it defeats the purpose; the point is to be present during the deferral decision, not to capture an email after it.

The deals are not being lost. They are being deferred into a release cycle, quietly, by people who never spoke to you. Naming the real competitor is the first step toward pricing the wait — and pricing the wait is the only argument that has been shown to move the number. For teams working through how this reshapes a full funnel, that is the work we do at Vital Voice.